{"id":22957,"date":"2023-01-11T01:38:00","date_gmt":"2023-01-10T17:38:00","guid":{"rendered":"https:\/\/flcube.com\/?p=22957"},"modified":"2025-01-25T01:40:27","modified_gmt":"2025-01-24T17:40:27","slug":"hkex-2022-annual-report-ipo-activity-declines-amid-global-challenges","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22957","title":{"rendered":"HKEX 2022 Annual Report: IPO Activity Declines Amid Global Challenges"},"content":{"rendered":"\n<p>The Hong Kong Exchanges and Clearing Ltd (HKEX) has released its annual report for 2022, highlighting a significant downturn in initial public offering (IPO) activity within the city. Overall, the number of new public listings fell by <strong>29.6% year-on-year (YOY)<\/strong> to just <strong>69 IPOs<\/strong>. In terms of capital raised, IPO funds totaled <strong>HKD 87.77 billion (USD 11.24 billion)<\/strong>, reflecting a substantial <strong>73.5% decrease YOY<\/strong>. This decline has been attributed to a challenging global macroeconomic and geopolitical environment, which has fostered \u201cweak sentiment and softness in the global IPO market.\u201d<\/p>\n\n\n\n<p>On a global scale, HKEX ranked as the <strong>fourth most popular venue for IPOs<\/strong> in 2022, trailing behind Shanghai, which secured the top position with IPOs exceeding <strong>USD 50 billion<\/strong>. Shenzhen followed closely with cumulative listing values just under <strong>USD 30 billion<\/strong>. According to a report from Ernst &amp; Young, the total number of IPOs worldwide plummeted by <strong>45%<\/strong> to <strong>1,333<\/strong>, with total values decreasing by <strong>61%<\/strong> to <strong>USD 179.5 billion<\/strong>. The US public listing market faced an even sharper decline, with IPO activity dropping by over <strong>90%<\/strong>, placing the Nasdaq and New York Stock Exchange at the <strong>9th<\/strong> and <strong>11th<\/strong> spots, respectively, in global rankings.<\/p>\n\n\n\n<p>Focusing on HKEX&#8217;s biotech sector, the situation was even more pronounced. The exchange hosted only <strong>7 companies<\/strong> that utilized Chapter 18A rules to list as pre-profit biotech firms, a decrease of approximately <strong>60% YOY<\/strong> from <strong>20 IPOs<\/strong> in 2021.<\/p>\n\n\n\n<p>In total, HKEX&#8217;s biotech listings raised <strong>HKD 3.4 billion (USD 440 million)<\/strong> during 2022, with <strong>Lepu Biopharma<\/strong> leading the way through an IPO of just under <strong>HKD 1 billion<\/strong> in October. The Shanghai-based biopharma company received its first indication approval for the PD-1 inhibitor <strong>pucotenlimab<\/strong> in September, while its pipeline includes a variety of clinical-stage antibody-drug conjugates (ADCs) and oncolytic viruses. Following Lepu, <strong>Jiangsu Recbio Technology<\/strong> secured the second position, with a pipeline featuring a protein-engineered recombinant COVID-19 vaccine. <strong>Biocytogen Pharmaceuticals<\/strong> came in third, raising over <strong>HKD 600 million<\/strong> in August, bolstered by recent clinical trial approvals for its PD-1 x CD40 bispecific antibody (BsAb) <strong>YH008<\/strong> in the US.<\/p>\n\n\n\n<p>Notably, there was a modest uptick in biotech IPO volumes during the latter half of the year, with three companies listing in December. Analysts anticipate that the recent reopening of China\u2019s borders will stimulate IPO activity and lead to a rebound in 2023. However, some speculate that the easing of delisting threats for Chinese firms on US exchanges may prompt more China-based companies to explore listings on the Nasdaq next year. This follows an agreement in August between US and Chinese securities regulators, allowing audit inspections by the US Public Company Accounting Oversight Board (PCAOB), which was followed by successful inspections and complete access to accounting records announced last month.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-hkex-biotech-listings-2022\">HKEX Biotech Listings, 2022<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Stock Code<\/th><th>Company Name at Time of Listing<\/th><th>Date of Prospectus (dd\/mm\/yy)<\/th><th>Date of Listing (dd\/mm\/yy)<\/th><th>Funds Raised (HK$)<\/th><\/tr><\/thead><tbody><tr><td>02157<\/td><td>Lepu Biopharma<\/td><td>10\/02\/22<\/td><td>23\/02\/22<\/td><td>$911,035,750<\/td><\/tr><tr><td>02179<\/td><td>Jiangsu Recbio Technology<\/td><td>21\/03\/22<\/td><td>31\/03\/22<\/td><td>$860,882,400<\/td><\/tr><tr><td>02315<\/td><td>Biocytogen Pharmaceuticals (Beijing)<\/td><td>19\/08\/22<\/td><td>01\/09\/22<\/td><td>$617,095,570<\/td><\/tr><tr><td>01244<\/td><td>3D Medicines Inc<\/td><td>29\/11\/22<\/td><td>15\/12\/22<\/td><td>$408,423,000<\/td><\/tr><tr><td>09877<\/td><td>Jenscare Scientific<\/td><td>23\/09\/22<\/td><td>10\/10\/22<\/td><td>$224,523,920<\/td><\/tr><tr><td>06955<\/td><td>Shandong Boan Biotechnology<\/td><td>19\/12\/22<\/td><td>30\/12\/22<\/td><td>$211,757,040<\/td><\/tr><tr><td>06922<\/td><td>Cryofocus Medtech (Shanghai)<\/td><td>16\/12\/22<\/td><td>30\/12\/22<\/td><td>$209,979,000<\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>The Hong Kong Exchanges and Clearing Ltd (HKEX) has released its annual report for 2022,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,27,72],"class_list":["post-22957","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-finanical-reports","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HKEX 2022 Annual Report: IPO Activity Declines Amid Global Challenges - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Hong Kong Exchanges and Clearing Ltd (HKEX) has released its annual report for 2022, highlighting a significant downturn in initial public offering (IPO) activity within the city. Overall, the number of new public listings fell by 29.6% year-on-year (YOY) to just 69 IPOs. In terms of capital raised, IPO funds totaled HKD 87.77 billion (USD 11.24 billion), reflecting a substantial 73.5% decrease YOY. This decline has been attributed to a challenging global macroeconomic and geopolitical environment, which has fostered \u201cweak sentiment and softness in the global IPO market.\u201d\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22957\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HKEX 2022 Annual Report: IPO Activity Declines Amid Global Challenges\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22957\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-10T17:38:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-24T17:40:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22957#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22957\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HKEX 2022 Annual Report: IPO Activity Declines Amid Global Challenges\",\"datePublished\":\"2023-01-10T17:38:00+00:00\",\"dateModified\":\"2025-01-24T17:40:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22957\"},\"wordCount\":490,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Finanical Reports\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22957#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22957\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22957\",\"name\":\"HKEX 2022 Annual Report: IPO Activity Declines Amid Global Challenges - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-01-10T17:38:00+00:00\",\"dateModified\":\"2025-01-24T17:40:27+00:00\",\"description\":\"The Hong Kong Exchanges and Clearing Ltd (HKEX) has released its annual report for 2022, highlighting a significant downturn in initial public offering (IPO) activity within the city. Overall, the number of new public listings fell by 29.6% year-on-year (YOY) to just 69 IPOs. In terms of capital raised, IPO funds totaled HKD 87.77 billion (USD 11.24 billion), reflecting a substantial 73.5% decrease YOY. This decline has been attributed to a challenging global macroeconomic and geopolitical environment, which has fostered \u201cweak sentiment and softness in the global IPO market.\u201d\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22957#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22957\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22957#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HKEX 2022 Annual Report: IPO Activity Declines Amid Global Challenges\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HKEX 2022 Annual Report: IPO Activity Declines Amid Global Challenges - Insight, China&#039;s Pharmaceutical Industry","description":"The Hong Kong Exchanges and Clearing Ltd (HKEX) has released its annual report for 2022, highlighting a significant downturn in initial public offering (IPO) activity within the city. Overall, the number of new public listings fell by 29.6% year-on-year (YOY) to just 69 IPOs. In terms of capital raised, IPO funds totaled HKD 87.77 billion (USD 11.24 billion), reflecting a substantial 73.5% decrease YOY. This decline has been attributed to a challenging global macroeconomic and geopolitical environment, which has fostered \u201cweak sentiment and softness in the global IPO market.\u201d","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22957","og_locale":"en_US","og_type":"article","og_title":"HKEX 2022 Annual Report: IPO Activity Declines Amid Global Challenges","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=22957","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-01-10T17:38:00+00:00","article_modified_time":"2025-01-24T17:40:27+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22957#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22957"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HKEX 2022 Annual Report: IPO Activity Declines Amid Global Challenges","datePublished":"2023-01-10T17:38:00+00:00","dateModified":"2025-01-24T17:40:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22957"},"wordCount":490,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Finanical Reports","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22957#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22957","url":"https:\/\/flcube.com\/?p=22957","name":"HKEX 2022 Annual Report: IPO Activity Declines Amid Global Challenges - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-01-10T17:38:00+00:00","dateModified":"2025-01-24T17:40:27+00:00","description":"The Hong Kong Exchanges and Clearing Ltd (HKEX) has released its annual report for 2022, highlighting a significant downturn in initial public offering (IPO) activity within the city. Overall, the number of new public listings fell by 29.6% year-on-year (YOY) to just 69 IPOs. In terms of capital raised, IPO funds totaled HKD 87.77 billion (USD 11.24 billion), reflecting a substantial 73.5% decrease YOY. This decline has been attributed to a challenging global macroeconomic and geopolitical environment, which has fostered \u201cweak sentiment and softness in the global IPO market.\u201d","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22957#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22957"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22957#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HKEX 2022 Annual Report: IPO Activity Declines Amid Global Challenges"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22957","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22957"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22957\/revisions"}],"predecessor-version":[{"id":22958,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22957\/revisions\/22958"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22957"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22957"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22957"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}